Rebecca J. Nagy

Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion

Zofia Piotrowska, Hideko Isozaki, Jochen K. Lennerz et al. · Cancer Discovery · 2018 · 434 citations

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies

Justin I. Odegaard, John J. Vincent, Stefanie Mortimer et al. · Clinical Cancer Research · 2018 · 428 citations

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients

Oliver A. Zill, Kimberly C. Banks, Stephen R. Fairclough et al. · Clinical Cancer Research · 2018 · 386 citations

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Luigi Formisano, Yao Lu, Alberto Servetto et al. · Nature Communications · 2019 · 383 citations · Full text

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer

Rosaria Condorelli, Laura M. Spring, Joyce O’Shaughnessy et al. · Annals of Oncology · 2017 · 377 citations · Full text